Back to Trials
NCT05495984NARecruiting

Neuroplasticity in Maternal Opioid Use Disorder (OUD)

Yale University

Start Date

1/1/2023

Completion Date

6/1/2026

Summary

Opioid use disorder (OUD) remains a major public health problem particularly for mothers in the perinatal period, for whom stress, relapse rates, and risk for overdose are elevated. The perinatal period is characterized by significant neural reorganization that determines outcomes for mothers and infants. OUD is also associated with neural reorganization, specifically neural circuitry implicated in stress regulation and reward processes. Interventions should therefore take advantage of this changing perinatal biology to enhance treatment response by targeting the aberrant neural circuitry compromised by maternal OUD. The investigators have developed and refined an evidence-based intervention for mothers with OUD designed to target these neural mechanisms and enhance the reward of caregiving; however, this has yet to be formally tested. Therefore, the investigators will examine maternal neuroplasticity using high-dense array electroencephalography (EEG) in mothers with OUD in response to our intervention. There will be 1 laboratory visit at pre-treatment, followed by 12 sessions of the evidence-based parenting intervention, and 1 laboratory visit at post-treatment. This study will attempt to validate the importance of taking advantage of the neuroplasticity in the perinatal period to optimize outcomes for mothers with OUD.

Detailed Description

This is a study conducted at the Child Study Center (CSC) in the Yale School of Medicine. It involves mothers in treatment for OUD who are caring for infants who are 4-12 months old. 15 mothers will complete 1 study visit, which will last 2.5 hours. It will start with informed consent and then will include demographics, EEG/ERP, a multidimensional assessment of mentalization (a brief self-report questionnaire, a 5-minute speaking task, and a one-hour interview) and several clinical measures (depression, anxiety, stressful life events). Participants will then complete 12 treatment (Mothering from the Inside Out (MIO)) visits, and 1 post-treatment data collection visit. Visits 2-13 (1 hour each) consist of participation in Mothering from the Inside Out (MIO). Visit 14 (2.5 hours) includes participation in the ERP paradigm and the multidimensional assessment of mentalization (a brief self-report questionnaire, a 5-minute speaking task, and a one-hour interview) and several clinical measures (depression, anxiety, stressful life events).

Eligibility Criteria

Age Range: 21 years to 45 years

Inclusion Criteria: * Biological mother of infants between 4-months and 12-months of age * 21-45 years of age at time of recruitment * Enrolled in substance use treatment and on mediation for opioid use disorder (MOUD). Exclusion Criteria: * Incapable of giving informed consent * Child spends less than 50% of time in mother's custody. * Non-English-speaking * Unable to complete the study because of pending legal cases or unable to supply two forms of contact for the purpose of follow-up * Physiological addiction to a substance that requires detoxification, defined as difficulties with physiological withdrawal from substances (e.g. delirium tremens, shaking, nausea).

Interventions

BEHAVIORAL

ERPs with electroencephalography (EEG)

BEHAVIORAL

MIO

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Opioid Use Disorder

Locations

Yale Child Studies Center

New Haven, Connecticut 06520

United States